Nektar Therapeutics (NKTR) Misses Q2 EPS by 2c

Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $34.6 million versus the consensus estimate of $34.23 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KB Home (KBH) PT Lowered to $50 at RBC Capital
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance